Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
MEMANTINE HYDROCHLORIDE
PHARMASCIENCE INC
N06DX01
MEMANTINE
10MG
TABLET
MEMANTINE HYDROCHLORIDE 10MG
ORAL
30/100
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0150423001; AHFS:
APPROVED
2009-11-04
PRODUCT MONOGRAPH PR PMS-MEMANTINE Memantine Hydrochloride Tablets, USP 5 mg and 10 mg N-methyl-D-aspartate (NMDA) receptor antagonist PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Ave., Suite 100 May 10, 2016 Montreal, Quebec H4P 2T4 www.pharmascience.com SUBMISSION CONTROL NO: 193961 _ _ _pms-MEMANTINE Product Monograph _ _Page 2 of 38_ NAME OF DRUG PR PMS-MEMANTINE Memantine Hydrochloride Tablets, USP THERAPEUTIC CLASSIFICATION N-methyl-D-aspartate (NMDA) receptor antagonist ACTION AND CLINICAL PHARMACOLOGY Persistent activation of the central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open channel) NMDA receptor antagonist, which binds preferentially to the NMDA receptor-operated cation channels. It blocks the effects of pathologically elevated sustained levels of glutamate that may lead to neuronal dysfunction. There is no clinical evidence that memantine prevents or slows neurodegeneration or alters the course of the underlying dementing process in patients with Alzheimer’s disease. Memantine exhibits low to negligible affinity for other receptors (GABA, benzodiazepine, dopamine, adrenergic, noradrenergic, histamine and glycine) or voltage-dependent Ca 2+ , Na + or K + channels. In addition, it does not directly affect the acetylcholine receptor or cholinergic transmission, which have been implicated in the cholinomimetic side effects (e.g., increased gastric acid secretion, nausea and vomiting) seen with acetylcholinesterase inhibitors. Memantine showed antagonist effects at the 5HT 3 receptor with a potency similar to that for the NMDA receptor. _In _ _vitro_ studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil or galantamine. PHARMACOKINETICS ABSORPTION Orally administered memantine is co Belgenin tamamını okuyun